Cipla Share Price (CIPLA)
Check the latest share price of Cipla, along with the price target, peer comparison, quarterly results, recent news, expert analysis, shareholding pattern, and other key fundamentals to make informed investment decisions.
as on 04:01PM, 13 Jun 2025
NSE
Cipla Stock Performance
Get live Cipla share price, day's high and low, historical returns, and market stats.
Day's Low
Day's High
₹1,480Day's Price Range₹1,510.552 Week's Low
52 Week's High
₹1,33552-Week Price Range₹1,702.05
| Returns % | |
| 1 Month Return | + 0.7 % |
| 3 Month Return | + 0.84 % |
| 1 Year Return | -3.81 % |
| 3 Year Return | + 56.03 % |
| 5 Year Return | + 133.85 % |
| Market Stats | |
| Previous Close | ₹1,502.80 |
| Open | ₹1,480.00 |
| Volume | 8.74L |
| Upper Circuit | ₹1,653.00 |
| Lower Circuit | ₹1,352.60 |
Cipla Fundamentals & Key Indicators
Check Cipla market cap, PE, PB, PEG ratios, dividend yield, and other key fundamental indicators.
Market Cap
₹1,21,573.55 Cr
Return on Equity (ROE)
15.5
PE Ratio (TTM)
23.05
Return on capital employed (ROCE)
20.1
Industry PE ratio
57.39
Beta (LTM)
0.71
P/B Ratio
4.31
Dividend Yield
0.87
PEG Ratio
1.62
Quarterly Earnings Growth YOY
31.1
EPS (TTM)
51.47
Sector
Pharmaceuticals
Book Value
330.79
Technical Analysis
Bullish
View Technical Analysis
How to invest in Cipla?
Investing in Cipla is simple. You can open a free INDstocks investment account on the INDmoney App. Search for Cipla or CIPLA on the app to check live prices of the stock and click on Buy or SIP. You can invest by selecting the number of shares or set up a fixed SIP to invest every month or week.
For example: You can buy 10 shares of Cipla or start an SIP based on the market price on each investment date.
You can easily transfer money to your stock account via the INDmoney app and start investing in stocks like Cipla with just a few clicks!
Cipla Stock's Interest Amongst Investors
Cipla Valuation
Track how Cipla P/E has moved over time to understand its valuation trends.
Cipla in the last 5 years
Lowest (18.11x)
March 19, 2020
Today (23.05x)
June 13, 2025
Industry (57.39x)
June 13, 2025
Highest (42.80x)
January 23, 2018
Today’s Price to Earnings Ratio: 23.05x
Cipla Stock Recommendation
Get updated buy, sell, and hold recommendations by analysts on Cipla.
based on 36 analysts
63.89%
Buy
19.44%
Hold
16.67%
Sell
63.89% of analysts recommend a 'BUY' rating for Cipla. Average target price of ₹1648.67
Source: S&P Global Market Intelligence
Cipla Share Price Target
Get share price movements and forecasts by analysts on Cipla.
Cipla price forecast by 36 analysts
Upside of9.53%
High
₹1875
Target
₹1648.67
Low
₹1280
Cipla target price ₹1648.67, a slight upside of 9.53% compared to current price of ₹1505.2. According to 36 analysts rating.
Excluding Excise Duty and Other Income, represents Net Revenue
Cipla revenue growth forecast
Expected growth rate Q1, FY2027:23.56%
Forecast
Actual
Including amortisation and stock based compensations
Cipla EPS growth forecast
EPS estimate Q1, FY2027:27.68%
Forecast
Actual
Source: S&P Global Market Intelligence
Cipla Financial Results
Get the annual and quarterly financial summary of Cipla, including revenue, profit, loss and more.
Indices Featuring Cipla Stock
Check stock indices that include Cipla.
Cipla Earnings and Dividends
View detailed summary of the earnings and dividend history of Cipla.
Cipla Ltd Earnings Results
Cipla Ltd’s net profit jumped 30.12% since last year same period to ₹1,221.84Cr in the Q4 2024-2025. On a quarterly growth basis, Cipla Ltd has generated -22.2% fall in its net profits since last 3-months.
Read More about Earnings ResultsCipla Ltd Dividends May,2024
In the quarter ending March 2024, Cipla Ltd has declared dividend of ₹13 - translating a dividend yield of 1.43%.
Read More about Dividends
Cipla Shareholding Pattern
View the shareholding pattern breakup of promoters, FIIs, DIIs, and retail investors in Cipla.
| Investors | Holdings % | Quarterly Trend | 3M change |
|---|---|---|---|
| Promoter Holdings | 29.13% | 0.00 | |
| Foreign Institutions | 26.22% | 0.00 | |
| Mutual Funds | 20.47% | 0.00 | |
| Retail Investors | 16.33% | 0.00 | |
| Others | 7.85% | 0.00 |
Cipla vs Peers
Compare market cap, revenue, PE, and other key metrics of Cipla with its industry peers.
Company | Analyst View | Market Cap(in ₹ Cr) | 5 Year CAGR | Debt to Asset Ratio | Net Profit(in ₹ Cr) | Yearly Revenue(in ₹ Cr) |
|---|---|---|---|---|---|---|
| BUY | 1,21,573.55 | 26.77% | 0.50 | 4,155 | 25,774 | |
| HOLD | 1,76,987.90 | 37.1% | 0.50 | 1,600 | 7,845 | |
| BUY | 1,10,074.44 | 32.82% | 0.67 | 1,656 | 10,727 | |
| BUY | 42,669.32 | -1.66% | 0.58 | 1,297 | 14,755 | |
| HOLD | 27,838.89 | -1.43% | 0.50 | 772 | 5,664 |
Cipla News & Key Events
Latest news and events in one place to help you make informed investing decisions in Cipla.
Cipla Ltd Gains Amid New Campaign Launch - 11 Jun, 2025
Cipla Ltd's stock rose 0.42%, continuing a five-day upward trend. The company also launched a new Cipladine campaign featuring Neena Gupta, enhancing brand visibility.Cipla Achieves Water Positivity Certification - 05 Jun, 2025
Cipla has been certified as a water positive organization by Bureau Veritas for its India operations. The company reduced water withdrawal by 13.1% and 67% of its manufacturing units operate with Zero Liquid Discharge systems.Cipla Appoints New CEO Following Leadership Changes - 01 Jun, 2025
Cipla Ltd underwent leadership changes after Kamil Hamied stepped down as chief strategy officer in 2015. Umang Vohra, previously with Dr. Reddy's Laboratories, was appointed global CFO and later became global CEO and managing director in 2016.Cipla Faces USFDA Observation at Bengaluru Plant - 30 May, 2025
Cipla's Bommasandra facility received a single observation from the USFDA following a cGMP inspection. The company plans to address the concerns promptly.Cipla Incorporates New Subsidiary in Germany - 29 May, 2025
Cipla has announced the incorporation of a wholly owned subsidiary, CiplaRna GmbH, in Germany, effective May 28, 2025. The new subsidiary aims to establish a laboratory focused on mRNA-based formulation and drug development support.Cipla's Growth Potential Amid Limited US Reliance - 27 May, 2025
Cipla is noted for its limited reliance on the US market, generating only 30% of its revenue from there. Analysts highlight a visible product pipeline and potential for growth in US earnings, contrasting with broader sector trends.Cipla Launches Film Showcasing Patient Commitment - 26 May, 2025
Cipla has launched an inspiring film as part of its 1935 Se Desh Ki Sehat Ke Saath campaign, highlighting its 90-year commitment to patient care and healthcare access. The film, inspired by real events during landslides in northern India, emphasizes Cipla's dedication to delivering life-saving treatments and its patient-first approach.Citi Reiterates Buy on Cipla Amid Market Challenges - 22 May, 2025
Citi has reiterated a 'Buy' rating on Cipla with a target price of ₹1,800, despite increasing competition in the Abraxane generic market. Meanwhile, Cipla shares experienced a slight dip to ₹1,475.10 with high trading volume.Cipla Reports Loss but Stock Gains - 21 May, 2025
Cipla reported a revenue of Rs 71.77 Cr and a significant net loss of Rs -342.51 Cr for 2025. Despite the losses, the stock gained 2.27% on the NSE.Cipla Shares Decline Amid High Trading Volume - 20 May, 2025
Cipla shares fell by 1.63% today, closing at Rs 1,467.30, with a trading volume of 1,575,329 shares. Despite the decline, the overall sentiment remains very bullish for Cipla's financial outlook.Cipla Reports Strong FY 25 Results and USFDA Update - 19 May, 2025
Cipla's Navi Mumbai Sitec Labs received a VAI classification from the USFDA. The company reported a 28% profit increase in FY 25, announcing a total dividend of INR16 per share.Cipla Reports Strong Q4 Results Amid Mixed Analyst Views - 14 May, 2025
Cipla's Q4 FY25 results show a 30% profit increase to Rs 1,222 crore. Despite a dividend announcement, analysts express mixed views on future margins and stock performance.
Insights on Cipla Ltd
Insights help you understand the recent movement of the company's critical parameters, giving you an overall view of the company.
POSITIVE IMPACTPrice Rise
In the last 3 months, CIPLA stock has moved up by 0.8%
- POSITIVE IMPACT
MF Holding Up
Mutual Funds have increased holdings from 20.42% to 20.47% in Mar 2025 quarter
NO EFFECTAgainst Peers
In the last 3 years, Torrent Pharmaceuticals Ltd has given 131.1% return, outperforming this stock by 75.0%
- NO EFFECT
Against Peers
In the last 1 year, Divis Laboratories Ltd has given 45.3% return, outperforming this stock by 49.1%
- NO EFFECT
Promoter Holding Unchanged
Promoters holdings remained unchanged at 29.13% of holdings in Mar 2025 quarter
NEGATIVE IMPACTFII Holding Down
Foreign Institutions have decreased holdings from 26.60% to 26.22% in Mar 2025 quarter
- NEGATIVE IMPACT
Profit Down
Netprofit is down for the last 2 quarters, 1.57K Cr → 1.22K Cr (in ₹), with an average decrease of 22.2% per quarter
- NEGATIVE IMPACT
Retail Holding Down
Retail Investor have decreased holdings from 16.41% to 16.33% in Mar 2025 quarter
- NEGATIVE IMPACT
Revenue Fall
Revenue is down for the last 2 quarters, 7.29K Cr → 7.01K Cr (in ₹), with an average decrease of 3.8% per quarter
About Cipla
Cipla's operations include manufacturing, marketing, and distribution of pharmaceuticals, biotechnology, and consumer healthcare products. Its top products include respiratory, anti-infectives, cardiovascular, and oncology drugs. Popular brands include Asthalin, Cipcal, Cifran, and Erythromycin. Cipla also manufactures nutraceuticals, herbal products, and over-the-counter medicines.
Revenue: ₹6,597.72Cr as on March 2025 (Q4 FY25)
Net Profit: ₹1,225.02Cr as on March 2025 (Q4 FY25)
Listing date: 03 Nov, 1994
Chairperson Name: Y K Hamied
| Organisation | Cipla Ltd |
| Industry | Pharmaceuticals |
| CEO | Y K Hamied |
| E-voting on shares | Click here to vote |
Mutual Funds that own Cipla
Check out the Mutual Funds with significant holdings in Cipla.
FAQs
What is Cipla share price today?
Cipla share price today stands at ₹1505.2, Open: ₹1480, Previous Close: ₹1502.8, High: ₹1510.5, Low: ₹1480, 52 Week High: ₹1702.05, 52 Week Low: ₹1335.
What is today's traded volume of Cipla?
Today's traded volume of Cipla is 8.74L. Which means that 8.74L shares of Cipla were bought and sold on the stock market during today's trading session.
What is Cipla's market cap today?
Today's market capitalisation of Cipla is ₹1,21,573.55 Cr. Market cap or market capitalisation is the total value of a company’s outstanding shares in the stock market, calculated by multiplying the current share price by the total number of shares issued by the company.
What is the 52 week high and 52 week low range of Cipla?
Cipla’s 52 week high is ₹1702.05 and 52 week low is ₹1335. The current share price of Cipla is ₹1505.2, which is -11.57% down from its 52 week high and 12.75% up from its 52 week low.